• V I Simanenkov, I V Maev, O N Tkacheva, S A Alekseenko, D Andreev, N V Bakulina, I G Bakulin, D S Bordin, T D Vlasov, N M Vorobyeva, V B Grinevich, I V Gubonina, M Y Drobizhev, N S Efremov, A E Karateev, Y V Kotovskaya, I Kravchuk, G G Krivoborodov, E V Kulchavenya, A M Lila, M V Maevskaya, A S Nekrasova, E A Poluektova, T V Popkova, O A Sablin, O I Solovyeva, A N Suvorov, G N Tarasova, D I Trukhan, and A V Fedotova.
• Mechnikov North-Western State Medical University.
• Terapevt Arkh. 2022 Oct 12; 94 (8): 940-956.

AbstractThis document was produced with the support of the National Medical Association for the Study of Comorbidities (NASС). In 2021 the first multidisciplinary National Consensus on the pathophysiological and clinical aspects of Increased Epithelial Permeability Syndrome was published. The proposed guidelines are developed on the basis of this Consensus, by the same team of experts. Twenty-eight Practical Guidelines for Physicians statements were adopted by the Expert Council using the "delphic" method. Such main groups of epithelial protective drugs as proton pump inhibitors, bismuth drugs and probiotics are discussed in these Guidelines from the positions of evidence-based medicine. The clinical and pharmacological characteristics of such a universal epithelial protector as rebamipide, acting at the preepithelial, epithelial and subepithelial levels, throughout gastrointestinal tract, are presented in detail.

8 keywords...

hide…